Europe Biobanks Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and Service (Equipment, Consumables, Service, and Software), Sample (Blood Products, Human Tissues, Cell Lines, and Others), and Application (Regenerative Medicine,

Europe Biobanks Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and Service (Equipment, Consumables, Service, and Software), Sample (Blood Products, Human Tissues, Cell Lines, and Others), and Application (Regenerative Medicine, Life Science Research, and Clinical Research)

The biobanks market in Europe is expected to grow from US$ 699.13 million in 2021 to US$ 1,070.46 million by 2028. It is estimated to grow at a CAGR of 6.3% from 2021 to 2028.

Virtual biobank is a virtual repository that provides data extracted and characterized from samples stored in a traditional biobank. Virtual biobank is an extensive database that provides high-resolution images of samples and other characteristic data. These biobanks can be accessed via specialized software or a web portal. Samples are stored in a decentralized manner. Virtual biobanks allow access to prerecorded data formats without accessing physical samples. Therefore, it is easy to share sample data without the fear of sample contamination/destruction/transportation.

Virtual biobanks are often used in bioinformatics. Virtual biobank is an online platform that contains 2D and 3D microscopy datasets of valuable clinical biopsy specimens. Recent advances in 3D tissue clearing technology have made it possible to create and display 3D image datasets along with traditional 2D micrographs used by pathologists and researchers. Each dataset has detailed de-identified clinicopathological and technical metadata, providing context for further research. Records are mentioned with each physical sample with biobanks, and those can also be obtained from the biobank using the provided contact details. Notably, the dataset has been made available to researchers and the public to encourage the use of clinical data.

Virtual biobanks have emerged as a practical option to improve sample visibility and access. An electronic database provides a global view of aggregated or individual standardized data about sample collections from dispersed institutions, regardless of where the samples are stored physically. Researchers can use virtual biobanks to identify the products and services they need to simplify and improve the management of each critical phase of the biobanking process. Thus, the virtual biobank is expected to emerge as a trend during the forecast period.

Italy, Spain, the UK, Germany, France, Russia, and Switzerland are highly affected among European countries. The economic conditions of these countries have been severely affected due to the exponential growth of COVID-19 cases in the region. Spain, Italy, Germany, France, and the UK are among the most affected European countries, and the number of deaths is massive. According to the International Health Regulation, the current coronavirus (COVID-19) outbreak has been declared by WHO as a Public Health Emergency of International Concern.

Biobanks have been helpful in the fight against COVID-19 because they have provided researchers with access to samples they need to explore while researching and creating vaccines and therapies. While the pandemic posed a significant problem for biobanks, it also offered a lucrative opportunity for future growth in many other research areas. It would have been impossible to make the genome of the SARS-CoV-2 virus accessible to the whole scientific community and produce efficient vaccinations in record time without samples from patients infected with Covid-19. Since the beginning of the pandemic, researchers have been requesting these samples to undertake tests to understand better the virus's various mechanisms for tricking human immune systems.

The Europe biobanks market is analyzed on the basis of product and services, sample, and application. Based on samples, the market is segmented into blood products, cell lines, human tissues, and others. In 2021, the blood products segment held the largest share in the market. Blood is one of the most common biosamples collected in human biobanks because it is a source of DNA and RNA. For this reason, anticoagulated blood is a prerequisite for plasma-derived cell-free circulating nucleic acid molecules and genomic or mitochondrial DNA and RNA. However, citrate is suitable for leukocyte culture. Storage conditions and quality of biospecimens are vital as they determine the yield of extracted DNA and RNA from a buffy coat or whole blood samples. The buffy coat and whole blood are needed for biobanks in human biospecimens. Whole blood refers to a sample that consists of red blood cells, platelets, plasma, and white blood cells. The buffy coat represents the white blood cells and platelets that form the anticoagulated blood sample.

The Europe biobanks market size has been derived using primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining an overview and forecast for the Europe biobanks market concerning all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain more analytical insights into the topic. Participants typically involved in this process include industry experts, such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants, such as valuation experts, research analysts, and key opinion leaders—specializing in the Europe biobanks market. THERMO FISHER SCIENTIFIC INC.; Tecan Trading AG; QIAGEN; Hamilton Company; Avantor, Inc.; MICRONICS JAPAN CO., LTD.; BD; Taylor-Wharton; Brooks Automation, Inc.; Promega Corporation; SciSafe Inc.; and Biovault Family are the leading companies in the market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe biobanks market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe biobanks market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the biobanks market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution